For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Comirnaty, Spikevax for PAFSC Review on April 25; HSC to Discuss 4th Shot on April 27
April 22, 2022
- LDP Adopts Proposal on 4th COVID-19 Vaccination, Urges Govt to Ponder Cost-Effectiveness
April 20, 2022
- Japan’s Lower House OKs PMD Law Amendment Bill
April 20, 2022
- SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
April 19, 2022
- Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
April 19, 2022
- Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
April 19, 2022
- Emergency Approval Plan Clears Lower House Panel; Opposition Bills Rejected, but Some Ideas Make It into Resolution
April 18, 2022
- Secure New mRNA Jabs, 4th Shots for Older Adults and People with Medical Conditions: LDP
April 18, 2022
- Japan PM Sees INES’ Macroeconomic Indexing Pitch as One Suggestion
April 18, 2022
- MHLW Panel to Review Rosacea Indication for Rozex on April 28
April 15, 2022
- No Major Safety Concerns for COVID-19 Jabs for Adults and Children: MHLW Panels
April 15, 2022
- Sort Out Challenges, Pricing Issues to Boost Innovation, Economic Security: CEFP
April 14, 2022
- MOF Urges Full Annual Price Cuts, “At Least Stepwise Reductions” in Adjustment Rate
April 14, 2022
- LDP Pharma Study Group Kicks Off Honebuto Debate, Wants Off-Year Price Cuts Scrapped
April 14, 2022
- Japan Can Get Refund on AstraZeneca Vaccine Cancellation: Minister
April 14, 2022
- Amicus Skips April Listing of MPS VII Therapy Mepsevii
April 14, 2022
- BMS’ CAR-T Therapy Abecma to Join NHI Price List on April 20
April 13, 2022
- Enhertu to Get 2.2% Price Cut in July under CEA Scheme
April 13, 2022
- Chuikyo OKs Listing of 8 Drugs on April 20; Vyvgart, Lumakras, and More
April 13, 2022
- Shionogi COVID Pill Doesn’t Meet “Presumed Efficacy” Criteria: HSC Subcommittee Chair
April 13, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…